Cochrane · systematic review · CD000208
Miscellaneous treatments for antipsychotic‐induced tardive dyskinesia
Soares‐Weiser, K, Rathbone, J, Ogawa, Y, et al. · Cochrane Database of Systematic Reviews · 2018 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
45
current version
GRADE rated
27
No studies
18
Included studies
NR
No studies 18 · 40%Ungraded 0 · 0%Very low 14 · 31.1%Low 11 · 24.4%Moderate 2 · 4.4%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Show all 2 versionsALKALOID ‐ DIHYDROGENATED ERGOT ALKALOIDS versus PLACEBO for antipsychotic‐induced tardive dyskinesia
Population: female and male 59‐80 (mean) years old patients with antipsychotic‐induced tardive dyskinesia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Tardive dyskinesia: No clinically important improvement ALKALOID ‐ DIHYDROGENATED ERGOT ALKALOIDS vs PLACEBO | RR 0.45 [0.21, 0.97] | 1 study · 28 participants | Low Downgraded: risk of bias, imprecision |
Tardive dyskinesia: Deterioration of symptoms ALKALOID ‐ DIHYDROGENATED ERGOT ALKALOIDS vs PLACEBO | RR 0.33 [0.01, 7.55] | 1 study · 28 participants | Very low Downgraded: risk of bias, imprecision |
Adverse effects ‐ any adverse effect ALKALOID ‐ DIHYDROGENATED ERGOT ALKALOIDS vs PLACEBO | RR 2.33 [0.75, 7.23] | 1 study · 28 participants | Very low Downgraded: risk of bias, imprecision |
Acceptability of treatment (measured by participants leaving the study early) ALKALOID ‐ DIHYDROGENATED ERGOT ALKALOIDS vs PLACEBO | RR 0.33 [0.02, 7.32] | 2 studies · 48 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported ALKALOID ‐ DIHYDROGENATED ERGOT ALKALOIDS vs PLACEBO | no estimate extracted | NR | No studies |
ANTIEPILEPTIC ‐ LEVETIRACETAM versus PLACEBO for antipsychotic‐induced tardive dyskinesia
Population: female and male 47‐54 years old (mean) patients with various psychiatric conditions and antipsychotic‐induced tardive dyskinesia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Tardive dyskinesia: No clinically important improvement ‐ not reported ANTIEPILEPTIC ‐ LEVETIRACETAM vs PLACEBO | no estimate extracted | NR | No studies |
Tardive dyskinesia: Deterioration of symptoms ‐ not reported ANTIEPILEPTIC ‐ LEVETIRACETAM vs PLACEBO | no estimate extracted | NR | No studies |
Adverse effects ‐ any adverse effect ANTIEPILEPTIC ‐ LEVETIRACETAM vs PLACEBO | RR 0.51 [0.25, 1.04] | 1 study · 69 participants | Low Downgraded: risk of bias, imprecision |
Acceptability of treatment (measured by participants leaving the study early) ANTIEPILEPTIC ‐ LEVETIRACETAM vs PLACEBO | RR 1.01 [0.46, 2.22] | 2 studies · 119 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported ANTIEPILEPTIC ‐ LEVETIRACETAM vs PLACEBO | no estimate extracted | NR | No studies |
ANXIOLYTIC ‐ BUSPIRONE versus PLACEBO for antipsychotic‐induced tardive dyskinesia
Population: female and male 33‐year old (mean) patients with schizophrenia and antipsychotic‐induced tardive dyskinesia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Tardive dyskinesia: No clinically important improvement ANXIOLYTIC ‐ BUSPIRONE vs PLACEBO | RR 0.53 [0.33, 0.84] | 1 study · 42 participants | Low Downgraded: risk of bias |
Tardive dyskinesia: Deterioration of symptoms ‐ not reported ANXIOLYTIC ‐ BUSPIRONE vs PLACEBO | no estimate extracted | NR | No studies |
Adverse effects ‐ not reported ANXIOLYTIC ‐ BUSPIRONE vs PLACEBO | no estimate extracted | NR | No studies |
Acceptability of treatment (measured by participants leaving the study early) ANXIOLYTIC ‐ BUSPIRONE vs PLACEBO | no estimate extracted | 1 study · 42 participants | Very low Downgraded: risk of bias |
Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported ANXIOLYTIC ‐ BUSPIRONE vs PLACEBO | no estimate extracted | NR | No studies |
ENZYME INHIBITOR ‐ VMAT2‐INHIBITOR (valbenazine) versus PLACEBO for antipsychotic‐induced tardive dyskinesia
Population: 18 to 85 year‐old patients with schizophrenia, schizoaffective disorder, mood disorder, or gastrointestinal disorder + antipsychotic‐induced tardive dyskinesia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Tardive dyskinesia: 1. No clinically important improvement ENZYME INHIBITOR ‐ VMAT2‐INHIBITOR (valbenazine) vs PLACEBO | RR 0.63 [0.46, 0.86] | 1 study · 92 participants | Moderate Downgraded: imprecision |
Adverse effects ‐ any adverse effect ENZYME INHIBITOR ‐ VMAT2‐INHIBITOR (valbenazine) vs PLACEBO | RR 1.5 [0.92, 2.45] | 1 study · 100 participants | Low Downgraded: imprecision |
Leaving the study early ENZYME INHIBITOR ‐ VMAT2‐INHIBITOR (valbenazine) vs PLACEBO | RR 1 [0.31, 3.25] | 1 study · 102 participants | Very low Downgraded: imprecision, indirectness |
FATTY ACID ‐ ETHYL‐EPA versus PLACEBO for antipsychotic‐induced tardive dyskinesia
Population: female and male 42 (mean) years old patients with schizophrenia or schizoaffective disorder and antipsychotic‐induced tardive dyskinesia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Tardive dyskinesia: No clinically important improvement ‐ not reported FATTY ACID ‐ ETHYL‐EPA vs PLACEBO | no estimate extracted | NR | No studies |
Tardive dyskinesia: Deterioration of symptoms ‐ not reported FATTY ACID ‐ ETHYL‐EPA vs PLACEBO | no estimate extracted | NR | No studies |
Adverse effects: EPS: parkinsonism measured by average ESRS change scores FATTY ACID ‐ ETHYL‐EPA vs PLACEBO | MD 0.3 | 1 study · 75 participants | Low Downgraded: risk of bias, imprecision |
Adverse effects: EPS: dystonia measured by average ESRS change scores FATTY ACID ‐ ETHYL‐EPA vs PLACEBO | no estimate extracted | 1 study · 75 participants | Low Downgraded: risk of bias, imprecision |
Adverse effects: EPS: akathisia measured by average ESRS change scores FATTY ACID ‐ ETHYL‐EPA vs PLACEBO | no estimate extracted | 1 study · 75 participants | Very low Downgraded: risk of bias, imprecision |
Acceptability of treatment (measured by participants leaving the study early) FATTY ACID ‐ ETHYL‐EPA vs PLACEBO | RR 0 | 1 study · 84 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported FATTY ACID ‐ ETHYL‐EPA vs PLACEBO | no estimate extracted | NR | No studies |
HERB ‐ GINKGO BILOBA versus PLACEBO for antipsychotic‐induced tardive dyskinesia
Population: male 45.2 (mean) years old patients with schizophrenia and antipsychotic‐induced tardive dyskinesia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Tardive dyskinesia: No clinically important improvement HERB ‐ GINKGO BILOBA vs PLACEBO | RR 0.88 [0.81, 0.96] | 1 study · 157 participants | Moderate Downgraded: imprecision |
Tardive dyskinesia: Deterioration of symptoms ‐ not reported HERB ‐ GINKGO BILOBA vs PLACEBO | no estimate extracted | NR | No studies |
Adverse effects ‐ not reported HERB ‐ GINKGO BILOBA vs PLACEBO | no estimate extracted | NR | No studies |
Acceptability of treatment (measured by participants leaving the study early) HERB ‐ GINKGO BILOBA vs PLACEBO | RR 0.25 [0.03, 2.22] | 1 study · 157 participants | Very low Downgraded: imprecision, indirectness |
Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported HERB ‐ GINKGO BILOBA vs PLACEBO | no estimate extracted | NR | No studies |
HORMONE ‐ MELATONIN versus PLACEBO OR NO TREATMENT for antipsychotic‐induced tardive dyskinesia
Population: female and male 28 to 91 years old patients with antipsychotic‐induced tardive dyskinesia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Tardive dyskinesia: No clinically important improvement HORMONE ‐ MELATONIN vs PLACEBO OR NO TREATMENT | RR 0.89 [0.71, 1.12] | 2 studies · 32 participants | Low Downgraded: imprecision, inconsistency |
Tardive dyskinesia: Deterioration of symptoms HORMONE ‐ MELATONIN vs PLACEBO OR NO TREATMENT | RR 0.22 [0.01, 4.05] | 1 study · 19 participants | Low Downgraded: imprecision |
Adverse effects HORMONE ‐ MELATONIN vs PLACEBO OR NO TREATMENT | no estimate extracted | 3 studies · 54 participants | Low Downgraded: imprecision |
Acceptability of treatment (measured by participants leaving the study early) HORMONE ‐ MELATONIN vs PLACEBO OR NO TREATMENT | no estimate extracted | 3 studies · 54 participants | Very low Downgraded: imprecision, indirectness |
Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported HORMONE ‐ MELATONIN vs PLACEBO OR NO TREATMENT | no estimate extracted | NR | No studies |
POLYPEPTIDE ‐ CERULETIDE versus PLACEBO for antipsychotic‐induced tardive dyskinesia
Population: female and male 55‐59 year old (mean) patients with various psychiatric conditions and antipsychotic‐induced tardive dyskinesia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Tardive dyskinesia: No clinically important improvement ‐ not reported POLYPEPTIDE ‐ CERULETIDE vs PLACEBO | no estimate extracted | NR | No studies |
Tardive dyskinesia: Deterioration of symptoms POLYPEPTIDE ‐ CERULETIDE vs PLACEBO | RR 0.97 [0.14, 6.8] | 2 studies · 103 participants | Low Downgraded: risk of bias, imprecision |
Adverse effects ‐ any adverse effect POLYPEPTIDE ‐ CERULETIDE vs PLACEBO | RR 1.32 [0.74, 2.36] | 2 studies · 122 participants | Low Downgraded: risk of bias, imprecision |
Acceptability of treatment (measured by participants leaving the study early) POLYPEPTIDE ‐ CERULETIDE vs PLACEBO | RR 1.09 [0.49, 2.4] | 1 study · 85 participants | Very low Downgraded: risk of bias, imprecision |
Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported POLYPEPTIDE ‐ CERULETIDE vs PLACEBO | no estimate extracted | NR | No studies |
HYPNOSIS or RELAXATION versus TAU for antipsychotic‐induced tardive dyskinesia
Population: female and male 35 (mean) years old patients with schizophrenia and tardive dyskinesia, acute extrapyramidal symptoms, and/or pseudoparkinsonism
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Tardive dyskinesia: No clinically important improvement HYPNOSIS or RELAXATION vs TAU | RR 0.45 [0.21, 0.94] | 1 study · 15 participants | Very low Downgraded: risk of bias, imprecision |
Tardive dyskinesia: Deterioration of symptoms HYPNOSIS or RELAXATION vs TAU | RR 0.18 [0.01, 3.81] | 1 study · 15 participants | Very low Downgraded: risk of bias, imprecision |
Adverse effects ‐ not reported HYPNOSIS or RELAXATION vs TAU | no estimate extracted | NR | No studies |
Acceptability of treatment (measured by participants leaving the study early) HYPNOSIS or RELAXATION vs TAU | no estimate extracted | 1 study · 15 participants | Very low Downgraded: risk of bias, imprecision |
Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported HYPNOSIS or RELAXATION vs TAU | no estimate extracted | NR | No studies |